France's Economy, Finances and Industry Minister Roland Lescure delivers a speech during the 8th Paris Finance Forum (PFF) organised by Paris Europlace at the Pavillon Gabriel in Paris on June 9, 2026. (Photo by Ludovic MARIN / AFP via Getty Images)

France's Economy, Finances and Industry Minister Roland Lescure delivers a speech during the 8th Paris Finance Forum (PFF) organised by Paris Europlace at the Pavillon Gabriel in Paris on June 9, 2026. (Photo by Ludovic MARIN / AFP via Getty Images)

France's Economy, Finances and Industry Minister Roland Lescure delivers a speech during the 8th Paris Finance Forum (PFF) organised by Paris Europlace at the Pavillon Gabriel in Paris on June 9, 2026. (Photo by Ludovic MARIN / AFP via Getty Images)

France's Economy, Finances and Industry Minister Roland Lescure delivers a speech during the 8th Paris Finance Forum (PFF) organised by Paris Europlace at the Pavillon Gabriel in Paris on June 9, 2026. (Photo by Ludovic MARIN / AFP via Getty Images)

This photograph shows an inside view with ultra-low temperature freezers (R) during the opening of a new centre dedicated to accelerating vaccine development of British pharmaceutical company GSK in Rixensart, on June 9, 2026. The British pharmaceutical giant GSK opens a new research centre in Belgium and also announced on June 9, 2026, that it had reached an agreement to acquire the US biopharmaceutical company Nuvalent, which specialises in the development of cancer therapies, "for $10.6 billion" (9.18 billion). (Photo by Eric LALMAND / POOL / AFP via Getty Images) / Belgium OUT

Employees work during the opening of a new centre dedicated to accelerating vaccine development of British pharmaceutical company GSK in Rixensart, on June 9, 2026. The British pharmaceutical giant GSK opens a new research centre in Belgium and also announced on June 9, 2026, that it had reached an agreement to acquire the US biopharmaceutical company Nuvalent, which specialises in the development of cancer therapies, "for $10.6 billion" (9.18 billion). (Photo by Eric LALMAND / POOL / AFP via Getty Images) / Belgium OUT

Belgium's Prime Minister Bart de Wever (L) attends the opening of a new centre dedicated to accelerating vaccine development of British pharmaceutical company GSK in Rixensart, on June 9, 2026. The British pharmaceutical giant GSK opens a new research centre in Belgium and also announced on June 9, 2026, that it had reached an agreement to acquire the US biopharmaceutical company Nuvalent, which specialises in the development of cancer therapies, "for $10.6 billion" (9.18 billion). (Photo by ERIC LALMAND / POOL / AFP via Getty Images) / Belgium OUT

Belgium's Prime Minister Bart de Wever attends the opening of a new centre dedicated to accelerating vaccine development of British pharmaceutical company GSK in Rixensart, on June 9, 2026. The British pharmaceutical giant GSK opens a new research centre in Belgium and also announced on June 9, 2026, that it had reached an agreement to acquire the US biopharmaceutical company Nuvalent, which specialises in the development of cancer therapies, "for $10.6 billion" (9.18 billion). (Photo by ERIC LALMAND / POOL / AFP via Getty Images) / Belgium OUT